< iframe width="425" elevation="355" src="https://www.youtube.com/embed/B1kldLAX2uk?rel=0" frameborder="0" allowfullscreen > CLICK “PROGRAM MORE” BELOW TO VIEW CHOSE IMPORTANT SAFETY AND SECURITY INFO, INCLUDING BOXED WARNING, AND ALSO FOR LINK TO PRESCRIBING INFO.
Meant for United States Medical Care Professionals.
Please see Important Security Information at http://bit.ly/2H1ZhNM.
Please see Prescribing Details, including Boxed Warning, at http://bit.ly/2s7TvzD.
Discover how to utilize the once-daily Saxenda ® injection pen with this step-by-step presentation. To make certain correct use and security, individuals need to always refer to the complete Guidelines for Usage in the Saxenda ® Medicine Overview prior to utilizing their pen. The Directions for Usage as well as Drug Guide can be located with the Saxenda ® pen. Discover more at https://bit.ly/2SZGdFr.
Picked Essential Security Info
————————————————————-
CAUTION: THREAT OF THYROID C-CELL TUMORS
Liraglutide creates dose-dependent and also treatment-duration-dependent thyroid C-cell tumors at scientifically appropriate exposures in both genders of rats and mice. It is unknown whether Saxenda ® creates thyroid C-cell tumors, consisting of medullary thyroid carcinoma (MTC), in humans, as the human significance of liraglutide-induced rodent thyroid C-cell lumps has not been established. Saxenda ® is contraindicated in people with a personal or household background of MTC as well as in clients with Numerous Endocrine Neoplasia syndrome type 2 (GUY 2). Counsel patients concerning the potential risk of MTC with usage of Saxenda ® and notify them of signs and symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine surveillance of lotion calcitonin or utilizing thyroid ultrasound is of unpredictable value for early discovery of MTC in clients treated with Saxenda ®
. ————————————————————- Indications as well as Usage Saxenda ®( liraglutide) shot 3 mg is indicated as an accessory to a reduced-calorie diet and also boosted physical activity for chronic weight management in: – Grownup people with an initial body mass index( BMI )of 30 kg/m2 or better( obesity) or
27 kg/m2 or greater( overweight) in the presence of a minimum of one weight-related comorbid problem( eg, high blood pressure, type 2 diabetic issues mellitus, or dyslipidemia ). – Pediatric people aged 12 years and older with body weight above 60 kg (132 pounds) as well as first BMI matching to 30 kg/m2 or better for grownups (obese) by worldwide cut-offs. Limitations of Usage. – Saxenda ® contains liraglutide and ought to not be coadministered with various other liraglutide-containing items or with various other GLP-1 receptor agonist. – The security and performance of Saxenda ® in pediatric patients with type 2 diabetes mellitus have actually not been developed.
– The safety and security as well as efficacy of Saxenda ® in combination with various other items planned for weight loss, including prescription medicines, non-prescription medicines, and also organic prep work, have not been developed. Essential Safety Info( cont ‘d). Contraindications. Saxenda ® is contraindicated in:. – People with an individual
or family background of MTC or MALE 2.
– Clients with a prior major hypersensitivity reaction to liraglutide or to any of the excipients in Saxenda ®. – Pregnancy. Cautions and Safety measures. – Threat of Thyroid C-cell Tumors: If lotion calcitonin is gauged as well as discovered
to be raised, the person should be additional reviewed. Individuals with thyroid blemishes kept in mind on physical examination or neck imaging must likewise be additional examined. – Severe Pancreatitis: Severe pancreatitis, consisting of fatal and also non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe individuals meticulously for symptoms and signs of pancreatitis( persistent extreme abdominal discomfort, sometimes emitting to the back with or without throwing up). If pancreatitis is presumed, stop Saxenda ® immediately as well as if pancreatitis is validated, do not restart. – Severe Gallbladder Illness: Considerable or rapid weight loss can increase the threat of cholelithiasis; nevertheless, the occurrence of severe gallbladder condition was higher in clients treated with Saxenda ® than with sugar pill also after representing the degree of weight loss. If cholelithiasis is presumed, gallbladder researches and ideal professional follow-up are shown. Please see complete Vital Security Information at http://bit.ly/2H1ZhNM. Saxenda ® as well as Victoza ® are signed up hallmarks of Novo Nordisk A/S. Novo Nordisk is a signed up hallmark of Novo Nordisk A/S. © 2021 Novo Nordisk All rights scheduled. US21SX00029
February 2021. Video Rating:/ 5